- Home
- KROS vs BGB Comparison
KROS vs BGB Comparison
Compare KROS & BGB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | KROS | BGB |
|---|---|---|
| Founded | 2015 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 584.9M | 527.0M |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | KROS | BGB |
|---|---|---|
| Price | $11.33 | $11.13 |
| Analyst Decision | Buy | |
| Analyst Count | 8 | 0 |
| Target Price | ★ $22.25 | N/A |
| AVG Volume (30 Days) | ★ 321.3K | 151.4K |
| Earning Date | 06-05-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 9.75% |
| EPS Growth | ★ 146.00 | N/A |
| EPS | ★ 2.30 | N/A |
| Revenue | ★ $243,864,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $4.92 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.12 | $10.47 |
| 52 Week High | $22.55 | $12.65 |
Technical Indicators
Market Signals| Indicator | KROS | BGB |
|---|---|---|
| Relative Strength Index (RSI) | 15.63 | 21.39 |
| Support Level | N/A | N/A |
| Resistance Level | $15.21 | $12.02 |
| Average True Range (ATR) | 0.69 | 0.09 |
| MACD | -0.38 | -0.03 |
| Stochastic Oscillator | 8.53 | 6.04 |
Price Performance
Historical ComparisonAbout KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.
About BGB Blackstone Strategic Credit 2027 Term Fund of Beneficial Interest
Blackstone Strategic Credit Fund is a closed-end term fund. Its primary investment objective is to seek high current income. The secondary objective of the fund is to seek the preservation of capital. Under normal market conditions, the Fund invests at least 80% of its Managed Assets in senior, secured floating-rate loans. The fund also invest in second-lien loans and high yield bonds and employs financial leverage, which may increase risk to the Fund. The Fund has a limited term and absent shareholder approval to extend the life of the Fund.